Recent advances in the genetics of cerebellar ataxias

Current Neurology and Neuroscience Reports

Volumn 12, Issue 3, 2012, Pages 227-236

  Sailer, Anna ^a   Houlden, Henry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebellar ataxia; Exome; Genetics; Next generation sequencing; SCA

Indexed keywords

CELL NUCLEUS DNA; ERYTHROPOIETIN; IDEBENONE; MITOCHONDRIAL DNA; POLYGLUTAMINE;

APRAXIA; ARTICLE; ATAXIA; ATAXIA TELANGIECTASIA; ATAXIAS WITH OCULOMOTOR APRAXIA; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CAG REPEAT; CEREBELLAR ATAXIA; DISEASE ASSOCIATION; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA SEQUENCE; EPISODIC ATAXIA; EPISODIC ATAXIA GENE; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; GENE MUTATION; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; INTRONIC REPEAT DISEASE; LOW DRUG DOSE; MEDICAL GENETICS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEXT GENERATION DNA SEQUENCING; NONHUMAN; PURE RECESSIVE CEREBELLAR ATAXIA; RUNDATAXIN GENE; SPINOCEREBELLAR DEGENERATION; SPORADIC ATAXIA; SYNE1 GENE; X LINKED CEREBELLAR ATAXIA;

ANIMALS; CEREBELLAR ATAXIA; EXOME; GENETIC LINKAGE; GENETICS, MEDICAL; HUMANS; MUTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861235522     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0267-6     Document Type: Article

References (78)

1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9(9):885-94.
2. Juvonen V, Hietala M, Kairisto V, Savontaus M-L. The occurrence of dominant spinocerebellar ataxias among 251 Finnish ataxia patients and the role of predisposing large normal alleles in a genetically isolated population. Acta Neurol Scand. 2005;111 (3):154-62. (Pubitemid 40278580)
3. Juvonen V, Hietala M, Päivärinta M, et al. Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion. Ann Neurol. 2000;48(3):354-61.
4. Kerber KA, Jen JC, Perlman S, Baloh RW. Late-onset pure cerebellar ataxia: differentiating those with and without identifiable mutations. J Neurol Sci. 2005;238(1-2):41-5. (Pubitemid 41560952)
5. Moseley ML, Benzow KA, Schut LJ, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology. 1998;51(6):1666-71. (Pubitemid 28565250)
6. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3(5):291-304. (Pubitemid 38510200)
7. Anheim M, Fleury M, Monga B, et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics. 2010;11(1):1-12.
8. Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the "the Drew family of Walworth.". Brain. 1982;105(Pt 1):1-28. (Pubitemid 12001376)
9. Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4(3):221-6. (Pubitemid 23205168)
10. Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14(3):269-76.
11. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8(3):221-8. (Pubitemid 24338732)
12. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997;15(1):62-9.
13. Nakamura K, Jeong SY, Uchihara T, et al. SCA17, A novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet. 2001;10 (14):1441-8. (Pubitemid 32684885)
14. Chong SS, McCall AE, Cota J, et al. Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1995;10 (3):344-50.
15. Koob MD, Moseley ML, Schut LJ, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet. 1999;21(4):379-84. (Pubitemid 29159573)
16. Matsuura T, Yamagata T, Burgess DL, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet. 2000;26(2):191-4.
17. Holmes SE, O'Hearn EE, McInnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. Nat Genet. 1999;23(4):391-2.
18. Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet. 2009;85(5):544-57.
19. Worth PF, Houlden H, Giunti P, Davis MB, Wood NW. Large, expanded repeats in SCA8 are not confined to patients with cerebellar ataxia. Nat Genet. 2000;24(3):214-5. (Pubitemid 30132186)
20. Brussino A, Graziano C, Giobbe D, et al. Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia. Mov Disord. 2010;25(9):1269-73.
21. Wang Y-C, Lee C-M, Lee L-C, et al. Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA12). J Biol Chem. 2011;286(24):21742-54.
22. Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied bymotor neuron involvement. Am J Hum Genet. 2011;89(1):121-30.
23. Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet. 2006;38(2):184-90. (Pubitemid 43177231)
24. Houlden H, Johnson J, Gardner-Thorpe C, et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet. 2007;39 (12):1434-6. (Pubitemid 350191351)
25. Bauer P, Stevanin G, Beetz C, et al. Spinocerebellar ataxia type 11 (SCA11) is an uncommon cause of dominant ataxia among French and German kindreds. J Neurol Neurosurg Psychiatr. 2010;81 (11):1229-32.
26. Bouskila M, Esoof N, Gay L, et al. TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. Biochem J. 2011;437(1):157-67.
27. Issa FA, Mazzochi C, Mock AF, Papazian DM. Spinocerebellar ataxia type 13 mutant potassium channel alters neuronal excitability and causes locomotor deficits in zebrafish. J Neurosci. 2011;31 (18):6831-41.
28. Figueroa KP, Minassian NA, Stevanin G, et al. KCNC3: phenotype, mutations, channel biophysics-a study of 260 familial ataxia patients. Hum Mutat. 2010;31(2):191-6.
29. Waters MF, Minassian NA, Stevanin G, et al. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet. 2006;38(4):447-51.
30. Yabe I, Sasaki H, Chen D-H, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol. 2003;60(12):1749-51. (Pubitemid 37521631)
31. van de Leemput J, Chandran J, Knight MA, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet. 2007;3(6):e108.
32. Hara K, Shiga A, Nozaki H, et al. Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology. 2008;71(8):547-51.
33. van de Leemput J, Wavrant-De Vrièze F, Rafferty I, et al. Sequencing analysis of the ITPR1 gene in a pure autosomal dominant spinocerebellar ataxia series. Mov Disord. 2010;25(6):771-3.
34. Knight MA, Hernandez D, Diede SJ, et al. A duplication at chromosome 11q12.2-11q12.3 Is associated with spinocerebellar ataxia type 20. Hum Mol Genet. 2008;17(24):3847-53.
35. Bakalkin G, Watanabe H, Jezierska J, et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet. 2010;87(5):593-603.
36. Misceo D, Fannemel M, Barøy T, et al. SCA27 caused by a chromosome translocation: further delineation of the phenotype. Neurogenetics. 2009;10(4):371-4.
37. Di Bella D, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet. 2010;42(4):313-21.
38. Cagnoli C, Stevanin G, Brussino A, et al. Missense mutations in the AFG3L2 proteolytic domain account for 1.5 % of European autosomal dominant cerebellar ataxias. Hum Mutat. 2010;31 (10):1117-24.
39. Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain. 2010;133(Pt 12):3510-8.
40. Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci. 2008;1142:250-3.
41. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-7. (Pubitemid 26089479)
42. Zühlke C, Laccone F, Cossée M, et al. Mutation of the start codon in the FRDA1 gene: linkage analysis of three pedigrees with the ATG to ATT transversion points to a unique common ancestor. Hum Genet. 1998;103(1):102-5. (Pubitemid 28398394)
43. Dupré N, Gros-Louis F, Chrestian N, et al. Clinical and genetic study of autosomal recessive cerebellar ataxia type 1. Ann Neurol. 2007;62(1):93-8. (Pubitemid 47235284)
44. Attali R,WarwarN, Israel A, et al. Mutation of SYNE-1, encoding an essential component of the nuclear lamina, is responsible for autosomal recessive arthrogryposis. Hum Mol Genet. 2009;18(18):3462-9.
45. Lagier-Tourenne C, Tazir M, López LC, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet. 2008;82(3):661-72. (Pubitemid 351735958)
46. Horvath R, Czermin B, Gulati S, et al. Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. J Neurol Neurosurg Psychiatry. 2012;83(2):174-8.
47. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268 (5218):1749-53.
48. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25(43):5906-11. (Pubitemid 44453446)
49. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132 (Pt 10):2688-98.
50. Al Tassan N, Khalil D, Shinwari J, et al. A missense mutation in PIK3R5 gene in a family with ataxia and oculomotor apraxia. Hum Mutat. 2012;33(2):351-4.
51. Doi H, Yoshida K, Yasuda T, et al. Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomal-recessive spinocerebellar ataxia with psychomotor retardation. Am J Hum Genet. 2011;89(2):320-7.
52. Vermeer S, Hoischen A, Meijer RP, Gilissen C, Neveling K, Wieskamp N, et al. Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet. 2010;87(6):813-9.
53. Assoum M, Salih MA, Drouot N, et al. Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia. Brain. 2010;133(Pt 8):2439-47.
54. Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet. 1995;9(2):141-5.
55. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57(1):127-30. (Pubitemid 32634862)
56. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009;17 (10):1359-62.
57. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010;19(R1): R83-9.
58. Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods. 2010;51(4):364-73.
59. Schicks J, Synofzik M, Schulte C, Schöls L. POLG, but not PEO1, is a frequent cause of cerebellar ataxia in central Europe. Mov Disord. 2010;25(15):2678-82.
60. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362-72.
61. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006;60(4):389-98. (Pubitemid 44684974)
62. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41(12):1308-12.
63. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009;65(5):610-4.
64. Montenegro G, Powell E, Huang J, et al. Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol. 2011;69(3):464-70.
65. Hildebrandt F, Heeringa SF, Rüschendorf F, et al. A systematic approach to mapping recessive disease genes in individuals from outbred populations. PLoS Genet. 2009;5(1):e1000353.
66. Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet. 2007;16(Spec No. 2):R115-23.
67. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamineinduced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10(8):816-20. (Pubitemid 39070854)
68. Tsou W-L, Soong B-W, Paulson HL, Rodríguez-Lebrón E. Splice isoform-specific suppression of the CaV2.1 variant underlying spinocerebellar ataxia type 6. Neurobiol Dis. 2011;43(3):533-42.
69. Todd PK, Oh SY, Krans A, et al. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet. 2010;6(12):e1001240.
70. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006;2(10):551-8. (Pubitemid 44413238)
71. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One. 2008;3(4):e1958.
72. Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord. 2008;23(13):1940-4.
73. Schmucker S, Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum Mol Genet. 2010;19(R1):R103-10.
74. Liu J, Tang T-S, Tu H, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci. 2009;29(29):9148-62.
75. Hourez R, Servais L, Orduz D, et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci. 2011;31(33):11795-807.
76. Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12(6):470-5
77. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, et al. Idebenone in Friedreich ataxia cardiomyopathyresults from a 6-month phase III study (IONIA). Am Heart J. 2011;161(3):639-645.e1
78. Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 (Suppl 1):42-5.